DCC-3014 manufacturers
- Vimseltinib
-
- $84.00
-
2026-07-27
- CAS:1628606-05-2
- Purity: 99.05%
- Supply Ability: 10g
- Vimseltinib
-
- $84.00
-
2026-07-27
- CAS:1628606-05-2
- Purity: 99.05%
- Supply Ability: 10g
|
| | DCC-3014 Basic information |
| Product Name: | DCC-3014 | | Synonyms: | DCC-3014;CSF1R,CD117,CSF-1 receptor,DCC 3014,SCFR,inhibit,c-Fms,DCC3014,c-Kit,CSF-1R,Vimseltinib,colony stimulating factor 1 receptor,Inhibitor;4(3H)-Pyrimidinone, 3-methyl-2-[(1-methylethyl)amino]-5-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-;2-(Isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one;DCC-3014(Vimseltinib);Vimseltinib (DCC-3014);Vimseltinib, 10 mM in DMSO;DCDCC-3014 | | CAS: | 1628606-05-2 | | MF: | C23H25N7O2 | | MW: | 431.49 | | EINECS: | | | Product Categories: | | | Mol File: | 1628606-05-2.mol |  |
| | DCC-3014 Chemical Properties |
| Boiling point | 609.2±65.0 °C(Predicted) | | density | 1.29±0.1 g/cm3(Predicted) | | solubility | DMF: 10 mg/ml
DMSO: 10 mg/ml
Ethanol: 10 mg/ml | | pka | 3.20±0.27(Predicted) | | form | Solid | | color | Off-white to light yellow | | InChI | InChI=1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27) | | InChIKey | TVGAHWWPABTBCX-UHFFFAOYSA-N | | SMILES | C1(NC(C)C)=NC=C(C2=NC(C)=C(OC3C=CN=C(C4=CN(C)N=C4)C=3)C=C2)C(=O)N1C |
| | DCC-3014 Usage And Synthesis |
| Uses | Vimseltinib (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC50s of <0.01 μM and 0.1-1 μM, respectively[1]. | | References | [1] Yumi Ahn, et al. 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities. WO2014145025A2.
[2] TIMOTHY M. CALDWELL. Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)[J]. Bioorganic & Medicinal Chemistry Letters, 2022, 74: Article 128928. DOI: 10.1016/j.bmcl.2022.128928 |
| | DCC-3014 Preparation Products And Raw materials |
|